Ergosuture — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Ergosuture is a private, pre-revenue medical device startup founded in 2019, headquartered in San Francisco. The company has developed a proprietary Roller-Based Suturing (RBS) technology platform, which forms the basis for its Drive'N Roll handheld laparoscopic device and robotic end-effectors, designed to significantly improve suturing efficiency and proficiency. Its pipeline extends beyond general surgery into a novel, suture-based transcatheter valve repair system targeting a large, underserved patient population. Ergosuture's value proposition targets improved surgical outcomes, reduced operative time, and sound hospital economics.

SurgeryCardiology

Technology Platform

Roller-Based Suturing (RBS) platform featuring instruments with rolling tips for self-righting/self-alignment of needles, reducing suturing steps and tissue force. Includes proprietary X-Needle design for flexibility and reduced trauma.

Opportunities

The large, underserved patient population with mitral/tricuspid valve regurgitation who are ineligible for surgery represents a multi-billion-dollar market for a successful transcatheter suture system.

Additionally, the constant pressure on hospitals to improve OR efficiency and reduce surgical times creates a strong value-based purchasing argument for devices that demonstrably shorten procedure duration.

Risk Factors

The company faces significant regulatory hurdles, particularly for its novel transcatheter heart valve program which will require extensive clinical trials.

Commercial adoption is challenging in a market dominated by large, entrenched competitors, and the company must prove its devices offer sufficient clinical and economic benefit to change standard surgical practice.

Competitive Landscape

Ergosuture competes in the surgical instrument space against giants like Medtronic, Johnson & Johnson (Ethicon), and Becton Dickinson, as well as robotic surgery leader Intuitive Surgical. Its differentiation lies in its unique roller-based mechanism aimed at simplifying suturing. In transcatheter valve repair, it would compete against Abbott (MitraClip) and Edwards Lifesciences, offering a suture-based alternative to clip-based therapies.

More companies in United States →